Supramolecular nanoparticles that target phosphoinositide-3-kinase overcome insulin resistance and exert pronounced antitumor efficacy

Cancer Research

Volumn 73, Issue 23, 2013, Pages 6987-6997

  Kulkarni, Ashish A ^a,b,c,e   Roy, Bhaskar ^a   Rao, Poornima S ^a   Wyant, Gregory A ^d   Mahmoud, Ayaat ^a   Ramachandran, Madhumitha ^a   Sengupta, Poulomi ^a,j   Goldman, Aaron ^a,b,e   Kotamraju, Venkata Ramana ^g,h   Basu, Sudipta ^a,c,i   Mashelkar, Raghunath A ^a,j   Ruoslahti, Erkki ^g,h   Dinulescu, Daniela M ^d,e   Sengupta, Shiladitya ^a,b,c,e,f  

^a Brigham and Women's Hospital   (United Kingdom)

^b HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

^c Indo US Joint Center for Nanobiotechnology   (United Kingdom)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g BURNHAM INSTITUTE   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ INDIAN INSTITUTE OF SCIENCE EDUCATION AND RESEARCH   (India)

^j NATIONAL CHEMICAL LABORATORY   (India)

more..

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 8 BROMO 2 MORPHOLIN 4 YL CHROMEN; CHROMENE DERIVATIVE; INITIATION FACTOR 4E BINDING PROTEIN 1; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; NANOPARTICLE; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PI 828; PROTEIN KINASE B; S6 KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; ENZYME INHIBITION; FEMALE; GLUCOSE HOMEOSTASIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INSULIN RESISTANCE; INSULIN SENSITIVITY; MOUSE; MULTIPLE CYCLE TREATMENT; NANOCHEMISTRY; NONHUMAN; OVARY CANCER; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; PROTEIN TARGETING;

EID: 84890278529     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-4477     Document Type: Article

References (33)

1. Boyle P, Levin B. World Cancer Report, World Health Organization, 2008.
2. Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 2004;4:361-370.
3. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009;9:28-39.
4. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 2005;5:161-171.
5. Sengupta S, Sasisekharan R. Exploiting nanotechnology to target cancer. Br J Cancer 2007;96:1315-1319.
6. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006;7:606-619.
7. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009;9:550-562.
8. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A 1999;96:4240-4245.
9. Workman P, Clarke PA, Raynaud FI, van Montfort RL. Drugging the PI3 kinome: from chemical tools to drugs in the clinic. Cancer Res 2010;70:2146-2157.
10. Knight ZA, Gonzalez B, Feldman ME. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 2006;125:733-747.
11. Bendell JC, Rodon J, Burris HA. Phase I, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 2012;30:282-290.
12. Raynaud FI, Eccles SA, Patel S. Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI103 through PI-540, PI-620 to the oral agent GDC0941. Mol Cancer Ther 2009;8:1725-1738.
13. Yuan F, Leunig M, Huang SK. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res 1994;54:3352-3356.
14. Harfouche R, Basu S, Soni S. Nanoparticle-mediated targeting of phosphatidylinositol-3-kinase signaling inhibits angiogenesis. Angiogenesis 2009;12:325-338.
15. Karve S, Werner ME, Sukumar R. Revival of the abandoned therapeutic wortmannin by nanoparticle drug delivery. Proc Natl Acad Sci U S A 2012;109:8230-8235.
16. Sengupta P, Basu S, Soni S. Cholesterol-tethered platinum II-based supramolecular nanoparticle increases antitumor efficacy and reduces nephrotoxicity. Proc Natl Acad Sci U S A 2012;109:11294-11299.
17. Lehn JM. Supramolecular chemistry: concepts and perspectives. New York, NY: VCH; 1995.
18. Lehn JM. Toward complex matter: supramolecular chemistry and self-organization. Proc Natl Acad Sci U S A 2002;99:4763-4768.
19. Chen KJ, Wolahan SM, Wang H. A small MRI contrast agent library of gadolinium(III)encapsulated supramolecular nanoparticles for improved relaxivity and sensitivity. Biomaterials 2011;32:2160-2165.
20. Gharbi SI, Zvelebil MJ, Shuttleworth SJ. Exploring the specificity of the PI3K family inhibitor LY294002. Biochem J 2007;404:15-21.
21. Sengupta S, Eavarone D, Capila I. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 2005;436:568-572.
22. Schipper ML, Iyer G, Koh AL. Particle size, surface coating, and PEGylation influence the biodistribution of quantum dots in living mice. Small 2009;5:126-134.
23. Seavey MM, Pan ZK, Maciag PC. A novel human Her-2/neu chimeric molecule expressed by Listeria monocytogenes can elicit potent HLA-A2 restricted CD8-positive T cell responses and impact the growth and spread of Her-2/neu-positive breast tumors. Clin Cancer Res 2009;15:924-932.
24. Miller TW, Rexer BN, Garrett JT, Arteaga CL. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res 2011;13:224.
25. Goldman AJRB, Ravi S, Rivera F, Kulkarni AA, Sengupta S. CD44 mediates chemotherapy tolerance through Akt and Ezrin/Radixin/Moesin in an EGFR-dependent manner. Cancer Res 2012;72:27.
26. Sugahara KN, Teesalu T, Karmali PP. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 2009;16:510-520.
27. Dinulescu DM, Ince TA, Quade BJ. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 2005;11:63-70.
28. Smith GC, Ong WK, Rewcastle GW, Kendall JD, Han W, Shepherd PR. Effects of acutely inhibiting PI3K isoforms and mTOR on regulation of glucose metabolism in vivo. Biochem J 2012;442:161-9.
29. Turke AB, Engelman JA. PIKing the right patient. Clin Cancer Res 2010;16:3523-3525.
30. Muranen T, Selfors LM, Worster DT. Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell 2012;21:227-239.
31. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010;28:1075-1083.
32. Clarke PA, Workman P. Phosphatidylinositide-3-kinase inhibitors: addressing questions of isoform selectivity and pharmacodynamic/predictive biomarkers in early clinical trials. J Clin Oncol 2012;30:331-333.
33. Sengupta S, Kulkarni A. Design principles for clinical efficacy of cancer nanomedicine: a look into the basics. ACS Nano 2013;7:2878-82.